CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Akebia Therapeutics Inc. (AKBA) on Thursday reported a first-quarter loss of $9.1 million, after reporting a profit in the same period a year earlier.
The Cambridge, Massachusetts-based company said it had a loss of 3 cents per share.
The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 1 cent per share.
The kidney disease treatment developer posted revenue of $53.5 million in the period, which also missed Street forecasts. Three analysts surveyed by Zacks expected $56.5 million.
The company’s shares closed at $1.49. A year ago, they were trading at $2.32.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on AKBA at https://www.zacks.com/ap/AKBA
Copyright © 2026 The Associated Press. All rights reserved. This material may not be published, broadcast, written or redistributed.
